Cargando…

Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?

BACKGROUND: There is immunohistochemical evidence to suggest that expression of epidermal growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in recurrent disease. This study investigates whether postoperative chemotherapy affects the degree of concordance betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalifa, Mahmoud A, Rowsell, Corwyn H, Gladdy, Rebecca, Ko, Yoo-Joung, Hanna, Sherif, Smith, Andy, Law, Calvin
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1705809/ https://www.ncbi.nlm.nih.gov/pubmed/17163999 http://dx.doi.org/10.1186/1477-7819-4-92

Ejemplares similares

Management of Metastatic Solid Pseudopapillary Cancer of the Pancreas: A Case Report
por: Dixon, Matthew, et al.
Publicado: (2013)

Porcine liver injury model to assess tantalum-containing bioactive glass powders for hemostasis
por: Nagrath, Malvika, et al.
Publicado: (2022)

Tissue stress from laparoscopic grasper use and bowel injury in humans: establishing intraoperative force boundaries
por: Khan, Amanda Farah, et al.
Publicado: (2021)

Utility of intraoperative pathology consultations of whipple resection specimens and their impact on final margin status
por: Sina, Niloofar, et al.
Publicado: (2023)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
por: ZHANG, Guowei, et al.
Publicado: (2022)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
por: Ballhausen, Alexej, et al.
Publicado: (2022)

Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib, et al.
Publicado: (2021)

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
por: Chen, R.-L., et al.
Publicado: (2017)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients
por: Beg, Mirza Masroor Ali, et al.
Publicado: (2019)

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
por: Peraldo-Neia, Caterina, et al.
Publicado: (2018)

Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Liu, Kai, et al.
Publicado: (2022)

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
por: Schneider, H. J., et al.
Publicado: (1997)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Author response to: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib A, et al.
Publicado: (2022)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
por: Kim, In Ae, et al.
Publicado: (2018)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
por: Hong, Lingzhi, et al.
Publicado: (2022)

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
por: Koba, Hayato, et al.
Publicado: (2021)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
por: Ye, Chenyang, et al.
Publicado: (2016)

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
por: Chen, Hualin, et al.
Publicado: (2020)

Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy
por: Xu, Bin, et al.
Publicado: (2023)

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
por: Wang, X, et al.
Publicado: (2014)

Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas
por: Lin, Wey-Ran, et al.
Publicado: (2019)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Erratum to NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
Publicado: (2022)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
por: Kim, Chi Hong, et al.
Publicado: (2015)

Metastatic Thymic Adenocarcinoma from Colorectal Cancer
por: Lee, Mina, et al.
Publicado: (2015)

Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
por: Kimura, Kenji, et al.
Publicado: (2019)

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
por: Carrasco, J, et al.
Publicado: (2015)

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone
por: ten Hoorn, Sanne, et al.
Publicado: (2021)

Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma
por: Wang, Pengchao, et al.
Publicado: (2022)

Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC
por: Jiang, Wei, et al.
Publicado: (2020)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami, Seigo, et al.
Publicado: (2017)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jmf1fu1us5cphp20cv7mioqqbf